Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. - Wikidata - awgldk - TriplyDB

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

http://www.wikidata.org/entity/Q33378868

about

How to select the best available related or unrelated donor of hematopoietic stem cells?Cord Blood as a Source of Natural Killer Cells Selection and expansion of natural killer cells for NK cell-based immunotherapy Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies Killer immunoglobulin-like receptors and tumor immunity Immunotherapeutic applications of NK cells Outcomes from unrelated donor hematopoietic stem cell transplantation Targeted immunotherapy for acute myeloid leukemia Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy Improving natural killer cell cancer immunotherapy Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.Biology and clinical effects of natural killer cells in allogeneic transplantation.Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.How closely related is graft-vs-leukemia to donor/recipient disparity?Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.Natural killer cell-based therapies.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I

P2860

Q26744109-B070FE40-7F58-4205-8C61-F0B20E9AA063 Q26771337-9951DE7F-3532-48DC-9A8A-E77AAE58FB3D Q26774777-C652A6C1-87A0-4783-B6AD-22A20A25292F Q26776538-FBE3D031-0DF9-4735-BBD7-D6D927930FEC Q26797345-3649FE18-51DF-4B36-B437-6A1E9F7A6D69 Q26996660-D265BBB2-7586-49A3-8DCA-42204183AEB8 Q27005792-EA58F058-2A1F-42E6-871A-828CD1790719 Q27015908-BD016F5B-20F1-430F-AB82-A25ED0A74A82 Q27027854-57EE9C95-DD9F-4D03-ACB8-BB7B678F4D10 Q27687636-F7638D96-6A7F-4C5E-A13F-6CA6A9CED641 Q28067102-C51313E0-9763-4DC9-A80D-F6B723D76CCB Q28080914-3679576D-487A-4921-AE7B-FAB89C8A0FDA Q28085397-B6262AF4-D431-49F3-9238-85138661599D Q28087719-BE03BF50-CB1C-4608-8E67-47869D7C895D Q28743897-2CA0F960-5BAB-44CC-B4B7-77D3C24B342C Q33558780-9EEAA73E-E274-418A-9367-FCD1489BBA86 Q33642419-34B0AECD-F522-490C-89FE-DBE99AC89C31 Q33643203-00DE8327-9A5A-4E1E-B54B-CD8E843B55E4 Q33645271-30F298BD-D592-4F25-9B5A-B077A0A9BB41 Q33651178-0C06645C-F109-42AA-96CF-EE39A2A6D4A3 Q33672480-74AE0C36-8F2E-4C54-BEA4-D9143CD92AD9 Q33703046-EF1CD567-37BB-47FD-9BBF-B4DD955FDE12 Q33765556-1703AFF1-7892-4406-87F7-F87F3A206329 Q33805980-7B3C7D82-B7A9-43A0-8EEF-6437B5EC3C2F Q33841389-17D8A28A-8B55-4F9C-BDAE-E2488627E6E7 Q33893173-537807A2-F507-4ED5-B25B-3D86C87E2C36 Q34009595-714274E2-6FB7-4D0A-9ABC-7650CDC02F50 Q34044024-682C5773-09FA-4E5E-AE7A-102B2694249B Q34087767-1128CEEF-959A-4896-B823-F809660B4388 Q34193507-473C2EA2-10A4-4B5A-BD5D-3F681D564E22 Q34202277-DE16118A-586C-4C8E-9FF1-51790046C826 Q34245469-3B48D096-588C-4A88-89E1-8D0B2EDADFF6 Q34412313-B0845EE3-3E80-4C6C-BE73-56BE4C5DD9FA Q34577711-CA724150-4A37-4B9C-9163-3C5C4A6B44AA Q34645259-9F67A521-D55E-4306-AD4D-EEFF56B5D519 Q34768153-A006C42D-11CF-426C-8795-C0C2053608DE Q34988727-BE773B6D-5453-40F9-8302-4D31473FA312 Q35029441-0D4DA724-99B8-4FD5-9FE3-243F700051D7 Q35070933-A207C90A-E4A7-4C78-AD6E-DE72119F1D10 Q35071326-CB39B529-42E5-4974-97B0-9AE11755D0AC

P2860

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

http://www.wikidata.org/entity/Q33378868

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@ast

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@en

type

label

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@ast

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@en

prefLabel

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@ast

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@en

P1433

Q33378868-BF11A747-11A8-482B-A55A-7B38174A7119

P1476

Q33378868-6E602841-BEA1-4900-ACF2-D3A1E5275234

P2093

Q33378868-10F53178-F348-461F-A03C-220D1BAD8852

Q33378868-1C784C4E-903F-42DB-BB44-0AE2A3F4A0F1

Q33378868-2AB310A1-6D96-4A0C-8CE3-E53F15323A6D

Q33378868-2BE21D84-E2F7-4CBA-BEF6-683DAB1735D6

Q33378868-72D446DA-BD4F-49FC-A6BD-68B560D81E91

Q33378868-97237A0F-85E9-4026-BDC4-F5CBCA28C6E3

Q33378868-A7A36BEA-E894-43D3-84C5-42E572D6046B

Q33378868-AF065087-0712-4A57-8B60-6BEC848EB76D

P2860

Q33378868-084AFAD7-7EC5-4F71-8A72-CFA584C56DEB

Q33378868-095F7699-F159-4451-80EB-E95EA708AE5C

Q33378868-1383B198-AE1A-415D-9BFD-EFFB0CAB5E21

Q33378868-1DE81E64-2BDD-414C-8320-1FB0430C5371

Q33378868-260940CA-7626-42B4-A3C1-3C6E619D8429

Q33378868-28237D6E-1E93-49C8-A8D7-7880CA0EB286

Q33378868-2E520FF1-818C-41DD-837E-55DE28EACE90

Q33378868-30C66F63-BDB7-4AEC-B2B9-771F0F47D182

Q33378868-363E0592-AAD6-4052-B0BB-192AC0EF5E3D

Q33378868-47CEC30A-ECC0-476D-BA63-68D95499F084

P304

Q33378868-C1ECC842-F745-4C9E-857A-06DC1947CB40

P31

Q33378868-51113FC7-CD68-4552-9A23-6E2619F82B3D

P356

Q33378868-E960C44D-4839-4E9B-B986-13A6BAFC725B

P407

Q33378868-E1E8CD3B-AB60-4FB5-BD4E-C4A4C55F317B

P433

Q33378868-C5932729-166A-4C64-91CF-034AC7E91F2A

P478

Q33378868-702FCB7C-1E9B-4806-9251-E72E61D3599D

P50

Q33378868-3BF02957-E9E9-478F-8182-23562DCA5201

Q33378868-6E2EDB07-DEAC-42A7-B4A1-F97562D921A1

Q33378868-8C32E985-191E-49B7-B2EF-738202483BB7

P577

Q33378868-74C3FBCE-6970-4A73-8CAE-02EDF544817C

P5875

Q33378868-60A42B88-45F0-4926-B029-0504991CAE06

P698

Q33378868-C069E047-8386-4314-9BA3-2DA6448C0B09

P921

Q33378868-F0D0E120-7C33-412B-BD6B-A65516C27A4D

P932

Q33378868-7BB415B9-607E-46C9-A1D8-A68979924214

P356

BLOOD-2008-07-171926

P1433

P1476

Donors with group B KIR haplot ...... or acute myelogenous leukemia.

@en

P2093

Chap T Le

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

Elizabeth Trachtenberg

http://www.w3.org/2001/XMLSchema#string

John Klein

http://www.w3.org/2001/XMLSchema#string

Koy Saeteurn

http://www.w3.org/2001/XMLSchema#string

Lisbeth A Guethlein

http://www.w3.org/2001/XMLSchema#string

Peter Parham

http://www.w3.org/2001/XMLSchema#string

Sarah Cooley

http://www.w3.org/2001/XMLSchema#string

P2860

In search of the 'missing self': MHC molecules and NK cell recognition

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles.

Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis.

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation.

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.

P304

726-732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-07-171926

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey S. Miller

Tracy L Bergemann

Steven G. E. Marsh

P577

2008-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23407608

http://www.w3.org/2001/XMLSchema#string

P698

18945962

http://www.w3.org/2001/XMLSchema#string

P921

P932

2628378

http://www.w3.org/2001/XMLSchema#string